rs780668
Positions:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_018344.6(SLC29A3):c.473C>T(p.Ser158Phe) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.701 in 1,613,958 control chromosomes in the GnomAD database, including 409,244 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign,drug response (★★).
Frequency
Genomes: 𝑓 0.61 ( 31114 hom., cov: 32)
Exomes 𝑓: 0.71 ( 378130 hom. )
Consequence
SLC29A3
NM_018344.6 missense
NM_018344.6 missense
Scores
2
6
9
Clinical Significance
Conservation
PhyloP100: 7.50
Genes affected
SLC29A3 (HGNC:23096): (solute carrier family 29 member 3) This gene encodes a nucleoside transporter. The encoded protein plays a role in cellular uptake of nucleosides, nucleobases, and their related analogs. Mutations in this gene have been associated with H syndrome, which is characterized by cutaneous hyperpigmentation and hypertrichosis, hepatosplenomegaly, heart anomalies, and hypogonadism. A related disorder, PHID (pigmented hypertrichosis with insulin-dependent diabetes mellitus), has also been associated with mutations at this locus. Alternatively spliced transcript variants have been described.[provided by RefSeq, Mar 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=3.6845643E-6).
BP6
Variant 10-71351651-C-T is Benign according to our data. Variant chr10-71351651-C-T is described in ClinVar as [Benign, drug_response]. Clinvar id is 130341.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr10-71351651-C-T is described in Lovd as [Benign].
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.755 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC29A3 | NM_018344.6 | c.473C>T | p.Ser158Phe | missense_variant | 4/6 | ENST00000373189.6 | NP_060814.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC29A3 | ENST00000373189.6 | c.473C>T | p.Ser158Phe | missense_variant | 4/6 | 1 | NM_018344.6 | ENSP00000362285 | P1 |
Frequencies
GnomAD3 genomes AF: 0.613 AC: 93188AN: 151976Hom.: 31124 Cov.: 32
GnomAD3 genomes
AF:
AC:
93188
AN:
151976
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.639 AC: 160758AN: 251472Hom.: 54270 AF XY: 0.650 AC XY: 88296AN XY: 135908
GnomAD3 exomes
AF:
AC:
160758
AN:
251472
Hom.:
AF XY:
AC XY:
88296
AN XY:
135908
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.711 AC: 1038771AN: 1461864Hom.: 378130 Cov.: 63 AF XY: 0.708 AC XY: 514870AN XY: 727236
GnomAD4 exome
AF:
AC:
1038771
AN:
1461864
Hom.:
Cov.:
63
AF XY:
AC XY:
514870
AN XY:
727236
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.613 AC: 93189AN: 152094Hom.: 31114 Cov.: 32 AF XY: 0.610 AC XY: 45321AN XY: 74356
GnomAD4 genome
AF:
AC:
93189
AN:
152094
Hom.:
Cov.:
32
AF XY:
AC XY:
45321
AN XY:
74356
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
2766
ALSPAC
AF:
AC:
2900
ESP6500AA
AF:
AC:
1615
ESP6500EA
AF:
AC:
6426
ExAC
AF:
AC:
77492
Asia WGS
AF:
AC:
1602
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign; drug response
Submissions summary: Benign:7Other:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:3
Benign, criteria provided, single submitter | clinical testing | Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan | Nov 12, 2023 | This variant is classified as Benign based on local population frequency. This variant was detected in 86% of patients studied by a panel of primary immunodeficiencies. Number of patients: 83. Only high quality variants are reported. - |
Likely benign, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | - | Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. - |
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 11, 2018 | - - |
H syndrome Benign:3
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 15, 2021 | - - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
not provided Benign:1Other:1
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jun 09, 2021 | This variant is associated with the following publications: (PMID: 28842327) - |
not provided, no classification provided | phenotyping only | GenomeConnect, ClinGen | - | Variant interpreted as Benign and reported on 04-27-2020 by Lab or GTR ID 500031. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. This variant was reported in an individual referred for clinical diagnostic genetic testing. - |
Gemcitabine response Other:1
drug response, criteria provided, single submitter | research | Bioinformatics Institute, Agency for Science, Technology and Research | Jan 01, 2017 | - correlated with patient outcome with gemcitabine-based chemotherpy |
Acanthosis nigricans Other:1
association, no assertion criteria provided | research | Clinical Genomics, Uppaluri K&H Personalized Medicine Clinic | - | Mutations in this gene can predispose to acanthosis nigricans in patients with insulin dependent diabetes. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D;D
MetaRNN
Benign
T;T;T
MetaSVM
Benign
T
MutationAssessor
Pathogenic
M;M;.
MutationTaster
Benign
P
PrimateAI
Uncertain
T
PROVEAN
Uncertain
.;D;.
REVEL
Benign
Sift
Benign
.;T;.
Polyphen
P;P;.
Vest4
0.31
MPC
0.39
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at